Browsing by 저자 : Se Hoon Park
전체 결과 9건 중 1-9 번을 표시중입니다.
-
1
Article
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial
Sun Young Rha
;
Toni K Choueiri
;
Vsevolod B Matveev
;
et al
2023
-
2
Article
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial
이재련
;
Andrea Necchi
;
Arjun V Balar
;
et al
2021
-
3
Article
Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure
Shinkyo Yoon
;
Sang Joon Shin
;
Ho Cheol Kim
;
et al
2022
-
4
Article
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Emmanuel S Antonarakis
;
Se Hoon Park
;
Jeffrey C Goh
;
et al
2023
-
5
Article
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Thomas Powles
;
Piotr Tomczak
;
Se Hoon Park
;
et al
2022
-
6
Article
Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure
Joo-Hwan Park
;
Inkeun Park
;
In-Ho Kim
;
et al
2022
-
7
Article
Radium-223 in Asian patients with castration-resistant prostate cancer with symptomatic bone metastases: A single-arm phase 3 study
이재련
;
Chung-Hsin Chen
;
Daqing Zhou
;
et al
2021
-
8
Article
Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy
Sang Joon Shin
;
Jae Lyun Lee
;
Tae Gyun Kwon
;
et al
2023
-
9
Article
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
강윤구
;
유민희
;
Hideo Baba
;
et al
2020